Immunosuppressive treatments in Crohn's disease induce myelodysplasia and leukaemia

Am J Hematol. 2010 Aug;85(8):634. doi: 10.1002/ajh.21755.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adolescent
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Budesonide / administration & dosage
  • Budesonide / adverse effects*
  • Budesonide / therapeutic use
  • Chromosomes, Human, Pair 7
  • Combined Modality Therapy
  • Crohn Disease / complications
  • Crohn Disease / drug therapy*
  • Cytarabine / administration & dosage
  • Drug Therapy, Combination
  • Etoposide / administration & dosage
  • Female
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Idarubicin / administration & dosage
  • Immunosuppressive Agents / adverse effects*
  • Immunosuppressive Agents / therapeutic use
  • Leukemia, Monocytic, Acute / drug therapy
  • Leukemia, Monocytic, Acute / etiology*
  • Leukemia, Monocytic, Acute / immunology
  • Leukemia, Monocytic, Acute / surgery
  • Male
  • Mercaptopurine / administration & dosage
  • Mercaptopurine / adverse effects*
  • Mercaptopurine / therapeutic use
  • Mesalamine / administration & dosage
  • Mesalamine / adverse effects*
  • Mesalamine / therapeutic use
  • Methyltransferases / deficiency
  • Methyltransferases / genetics
  • Monosomy
  • Myelodysplastic Syndromes / etiology*
  • Myelodysplastic Syndromes / genetics
  • Myelodysplastic Syndromes / immunology
  • Myelodysplastic Syndromes / surgery
  • Prednisone / adverse effects*
  • Prednisone / therapeutic use
  • Young Adult

Substances

  • Immunosuppressive Agents
  • Cytarabine
  • Mesalamine
  • Budesonide
  • Etoposide
  • Mercaptopurine
  • Methyltransferases
  • thiopurine methyltransferase
  • Prednisone
  • Idarubicin